Skip to main content
Caplight Logo









Alaya.bio

Alaya.bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.alaya.bio/

Last Round

Series A

Jul 10, 2026

Total Funding Raised

$9.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Alaya.bio is a biotechnology company developing a proprietary polymeric nanoparticle platform for in-vivo CAR-T cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

in vivo gene deliveryCAR-T immunotherapypolymeric nanoparticlesin vivo CAR-Tgene therapycell engineeringlentiviral vectorsimmuno-oncologydrug delivery platformbiotech licensingin situ reprogrammingnext-gen CAR-Toff-the-shelf CAR-Tnanomedicinebiotech partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alaya.bio Comparables

Compare Alaya.bio with similar companies based on industry and business-model similarity.

Alaya.bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aera Therapeutics
86%
Abintus Bio
82%
Ensoma
82%

Alaya.bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 10, 2026
SeedDec 1, 2022
Pre SeedAug 8, 2022

Alaya.bio Investors

Notable investors and investment history

Alaya.bio investors
InvestorRounds
AgoranovSeed
Mission BioCapitalPre Seed
Volnay TherapeuticsPre Seed, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 10, 2026

    Raised $10.9M pre-money valuation.

  • Aug 8, 2022

    $3M round led by Mission BioCapital and Volnay Therapeutics.

Alaya.bio Filings

Explore SEC and related filing metadata, where available.

Alaya.bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Alaya.bio's valuation, stock price, and market status.

Is Alaya.bio a public or private company?

Alaya.bio is a private company.

What is the current stock price of Alaya.bio?

Alaya.bio is a private company with no public stock price. No recent secondary market data is available.

How much is Alaya.bio worth (valuation)?

Valuation information for Alaya.bio is not publicly available.

Can I buy Alaya.bio stock?

Alaya.bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Alaya.bio's last funding round?

Alaya.bio's most recent funding round was Seed on December 1, 2022.

Who are the main investors in Alaya.bio?

Key investors in Alaya.bio include Agoranov, Volnay Therapeutics.

Will Alaya.bio IPO soon?

No public IPO plans have been announced for Alaya.bio.

How can I track Alaya.bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alaya.bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range18
Year Founded2022
Last FundingJul 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?